New products
ARUP introduces spectral flow assay for multiple myeloma
ARUP Laboratories launched CLARISPECT Multiple Myeloma MRD, a spectral flow cytometry assay for detecting minimal residual disease in multiple myeloma patients. The assay represents a clinical offering from ARUP's diagnostic laboratory services and is designed to support treatment monitoring and patient stratification in hematologic malignancy care.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network